Covestor Ltd Makes New Investment in Repligen Co. (NASDAQ:RGEN)

Covestor Ltd purchased a new position in shares of Repligen Co. (NASDAQ:RGENGet Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 305 shares of the biotechnology company’s stock, valued at approximately $81,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Confluence Wealth Services Inc. purchased a new position in shares of Repligen in the 4th quarter worth $27,000. Assetmark Inc. acquired a new stake in Repligen in the 3rd quarter valued at $49,000. Sageworth Trust Co of South Dakota acquired a new stake in Repligen in the 4th quarter valued at $46,000. UMB Bank N A MO acquired a new stake in Repligen in the 4th quarter valued at $59,000. Finally, Fieldpoint Private Securities LLC grew its stake in shares of Repligen by 36.8% during the third quarter. Fieldpoint Private Securities LLC now owns 260 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 70 shares in the last quarter. 86.82% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:RGEN opened at $154.68 on Wednesday. The company has a market capitalization of $8.42 billion, a price-to-earnings ratio of 61.14 and a beta of 0.98. Repligen Co. has a one year low of $137.21 and a one year high of $327.32. The stock has a 50-day simple moving average of $166.13 and a 200 day simple moving average of $207.72.

Repligen (NASDAQ:RGENGet Rating) last posted its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.20. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The business had revenue of $206.40 million during the quarter, compared to the consensus estimate of $185.48 million. During the same period last year, the firm earned $0.68 earnings per share. The company’s revenue for the quarter was up 44.5% compared to the same quarter last year. As a group, analysts expect that Repligen Co. will post 3.1 earnings per share for the current fiscal year.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.10% of the company’s stock.

Several analysts have recently weighed in on the company. assumed coverage on Repligen in a research note on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating and set a $190.00 target price for the company. in a research note on Monday, February 21st. Craig Hallum lowered their target price on Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Finally, SVB Leerink lowered their target price on Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $285.57.

Repligen Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Want to see what other hedge funds are holding RGEN? Visit to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENGet Rating).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.